

## Hybrigenics 2015 first-half results and highlights

- **Stable turnover at EUR 1.9 million**
- **Net loss contained at EUR 2.3 million**
- **Doubling of cash position to EUR 14.8 million**
- **Inecalcitol designated Orphan drug for Acute Myeloid Leukemia both in Europe and the United States**

**Paris, 19 October 2015** – Hybrigenics (FR0004153930 - ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments of proliferative diseases and specialised in proteomic and genomic scientific services, today presents its consolidated accounts for the first half of 2015.

### 2015 first-half results

<b>EUR (million)</b>	<b>H1 2015</b>	H1 2014	Change (%)
<b>Total turnover</b>	<b>1.9</b>	1.9	=
Other operating revenues <sup>a</sup>	0.4	0.5	-20%
<b>Total operating revenues</b>	<b>2.3</b>	2.4	-4%
<b>Operating costs</b>	<b>5.6</b>	4.8	+17%
<b>Operating result</b>	<b>-3.3</b>	-2.4	+38%
<b>Net result</b>	<b>-2.3</b>	-2.1	+10%
<b>Net cash position</b> (as of June 30 <sup>th</sup> )	<b>14.8</b>	7.4	+100%

<sup>a</sup> mainly research subsidies, subleases and services to subleasers

Hybrigenics' total turnover remained stable. Operating costs increased by EUR 0.8 million as a result of the launch of a new Phase II clinical study in chronic myeloid leukemia and of the preparation and filing of Orphan drug designations for acute myeloid leukemia (AML). Consequently, the operating loss increased by EUR 0.9 million. However, the net loss remained limited to the same level as last year, slightly higher than EUR 2 million, due to an increase in research tax credit in H1 2015 in relation to the Research Tax Credit applied for the first time by Hybrigenics Services SAS during the first semester 2015.

The Orphan drug designation has been definitely granted to inecalcitol for AML by the European Commission on July 28, 2015 following the positive opinion adopted by the European Medicines Agency (see Hybrigenics' press release of June 22, 2015). The same Orphan drug designation for AML has been granted to inecalcitol in the United States by the American Food and Drug Administration (see Hybrigenics' press release of August 10, 2015).

# HYBRIGENICS

## Press Release

Hybrigenics' cash position on June 30<sup>th</sup>, 2015 amounted to EUR 14.8 million, exactly twice as much as on June 30<sup>th</sup>, 2014, and 54% more than the EUR 9.6 million on December 31<sup>st</sup>, 2014, thanks to a successful capital raise of EUR 9 million completed during the first half of 2015 (see Hybrigenics' press release of April 7<sup>th</sup>, 2015).

This capital raise was the third in 18 months during which Hybrigenics' net equity has been replenished from EUR 2.4 million at the end of 2013, to EUR 7.2 million on June 30, 2014, to EUR 11.0 million at the end of 2014 and up to EUR 17.2 million as of June 30, 2015.

*"Thanks to this financial achievement and to the recent Orphan drug designations, Hybrigenics is now actively preparing a clinical Phase II study of inecalcitol in acute myeloid leukemia, the most challenging and rewarding therapeutic indication among adult leukemias, both in France and in the United States,"* said Remi Delansorne, Hybrigenics' CEO.

### **About Hybrigenics**

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere<sup>®</sup>, which is the current gold-standard chemotherapeutic treatment for this indication. Inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. A clinical Phase II study of inecalcitol is currently ongoing in chronic myeloid leukemia patients.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes (DUBs) and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. A first milestone has been achieved in a drug discovery program targeting one DUB in oncology.

Hybrigenics Services ([www.hybrigenics-services.com](http://www.hybrigenics-services.com)) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Helixio ([www.helixio.com](http://www.helixio.com)), Hybrigenics' genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500. Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

\*\*\*

**HYBRIGENICS is listed on the Alternext market of Euronext Paris**

**ISIN: FR0004153930**

**Ticker: ALHYG**



**Hybrigenics**  
Rémi Delansorne  
CEO  
Tel.: +33 (0)1 58 10 38 00  
[investors@hybrigenics.com](mailto:investors@hybrigenics.com)

**NewCap**  
Financial communication  
Julien Perez / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
[hybrigenics@newcap.fr](mailto:hybrigenics@newcap.fr)